Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04139902
Recruitment Status : Not yet recruiting
First Posted : October 25, 2019
Last Update Posted : January 6, 2020
Sponsor:
Collaborator:
Tesaro, Inc.
Information provided by (Responsible Party):
Diwakar Davar, University of Pittsburgh

Brief Summary:
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.

Condition or disease Intervention/treatment Phase
Melanoma Stage III Melanoma Stage IV Drug: Dostarlimab (TSR-042) (singly) Drug: Dostarlimab (TSR-042) and TSR-022 (combination) Phase 2

Detailed Description:

This is a randomized phase II neoadjuvant study comparing neoadjuvant therapy with PD-1 inhibitor Dostarlimab (TSR-042) to the PD-1/TIM-3 inhibitor combination Dostarlimab (TSR-042)/TSR-022 in patients with resectable regionally advanced or oligometastatic melanoma.

Patients with stage III B/C/D or oligometastatic stage IV A melanoma with lymph node (LN) and/or in-transit and/or oligometastatic disease who have yet to undergo definitive surgery are eligible to enroll.

Suitable patients will be identified pre-operatively. Patients will undergo screening evaluation consisting of systemic/CNS staging scans, tumor biopsy, blood studies to confirm suitability. Subjects will receive neoadjuvant therapy (Dostarlimab (TSR-042) or Dostarlimab (TSR-042)/TSR-022 combination for 6 weeks prior to planned surgery (pre-operative phase). Surgery will occur 1-4 weeks after completion of pre-operative therapy. After recovery from surgery subjects will receive Dostarlimab (TSR-042) (maintenance phase) for approximately 48 weeks; for a total of 54 weeks of study drug(s) administration in total.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Neoadjuvant Study of PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) in Resectable Stage III or Oligometastatic Stage IV Melanoma (Neo-MEL-T)
Estimated Study Start Date : March 15, 2020
Estimated Primary Completion Date : March 15, 2022
Estimated Study Completion Date : December 15, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Dostarlimab (TSR-042) (singly)

Pre-operative Phase:

Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.

Post-operative Phase:

Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks.

Drug: Dostarlimab (TSR-042) (singly)

If patients are randomized to Dostarlimab (TSR-042) alone, during the Pre-operative Phase, 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.

Surgery will occur 1-4 weeks after completion of the pre-operative phase.

During the Post-operative phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks.

Other Name: Dostarlimab

Experimental: Dostarlimab (TSR-042) and TSR-022 (combination)

Pre-operative Phase:

Dostarlimab (TSR-042) 500mg and TSR-022 900mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1 and then again on Cycle 2 Day 1.

Post-operative Phase:

Dostarlimab (TSR-042) will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks. TSR-022 will not be administered.

Drug: Dostarlimab (TSR-042) and TSR-022 (combination)

If patients are randomized to the combination, Dostarlimab (TSR-042) and TSR-022, during the Pre-operative Phase, Dostarlimab (TSR-042) 500mg and TSR-022 900mg will be administered through an IV over 30 minutes on Cycle 1 Day 1 and then again on Cycle 2 Day 1.

Surgery will occur 1-4 weeks after completion of the pre-operative phase.

During the Post-operative Phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks.





Primary Outcome Measures :
  1. Major Pathologic Response (MPR) [ Time Frame: 54 weeks ]
    Proportion of patients with an RVT (residual volume of viable tumor) of ≤10% remaining in post-therapy specimen using immunotherapy-specific pathologic assessment of neoadjuvant treated melanoma specimens.


Secondary Outcome Measures :
  1. Number of Participants Experiencing Adverse Events Attributed to Treatment [ Time Frame: Up to 56 months ]
    Number o f participants experiencing adverse events (per CTCAE v5.0) that are possibly, probably or definitely related to study treatment, will be tabulated by category, grade and relatedness.

  2. Frequency of Delays in Surgery [ Time Frame: Up to 56 months ]
    Number of delayed of surgeries.

  3. Frequency of Cancellations of Surgery [ Time Frame: Up to 56 months ]
    Number of canceled surgeries.

  4. Relapse-free Survival [ Time Frame: Up to 56 months ]
    The length of time from initiation of study drug(s) until melanoma relapse (disease progression) as defined by RECIST v1.1, or death. Progressive Disease (PD): ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

  5. Overall Survival (OS) [ Time Frame: Up to 56 months ]
    The length of time from initiation of study drug(s) that patients remain alive.


Other Outcome Measures:
  1. Percentage of Circulating immune cells [ Time Frame: Up to 56 months ]
    Percentage of immune cells present in circulating peripheral blood.

  2. Percentage of Intratumoral immune cells [ Time Frame: Up to 56 months ]
    Percentage of immune cells present in tumor.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • written informed consent for the study
  • ≥ 18 years of age
  • histologically or cytologically confirmed diagnosis of cutaneous or unknown primary melanoma (excluding uveal/choroidal and mucosal melanoma; although acral melanoma is included) belonging to one of the following AJCC 8th edition TNM stages:

    1. Tx or T1-4 AND
    2. N1b, or N1c, or N2b, or N2c, or N3b, or N3c AND/OR
    3. M1a, or M1b
  • Presentation for primary melanoma with concurrent regional nodal and/or in-transit metastasis and/or oligometastasis; AND/OR at the time of clinical detected nodal and/or in-transit and/or oligometastatic recurrence (resectability determination/deemed resectable at baseline to be eligible), includes: Primary melanoma with clinically apparent regional lymph node metastases; Clinically detected recurrent melanoma at the proximal regional lymph node(s) basin; Clinically detected primary melanoma involving multiple regional nodal groups; Clinical detected nodal melanoma (if single site) arising from an unknown primary; In-transit and/or satellite metastases with or without regional lymph node involvement; Distant skin and/or in-transit and/or satellite metastases with or without regional lymph node involvement
  • measurable disease based on RECIST 1.1
  • must provide tumor tissue from a newly obtained core, punch, incisional or excisional tumor biopsy
  • 0 or 1 on the ECOG Performance Scale
  • Demonstrate adequate organ function on screening labs obtained within 14 days of registration
  • negative serum pregnancy test (females of childbearing potential)
  • females of non-childbearing potential must be ≥45 years of age and has not had menses for >1 year; if amenorrhoeic for <2 years without history of a hysterectomy and oophorectomy must have an FSH value in the postmenopausal range; post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation (documented hysterectomy or oophorectomy)
  • male subjects should agree to use an adequate method of contraception

Exclusion Criteria:

  • Patients with uveal and/or mucosal melanoma histology are excluded (Patients with melanoma of unknown histology are permitted to enroll)
  • Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.
  • Is receiving immunosuppression for active autoimmune disease: history of active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids (>10mg daily prednisone or equivalent) or systemic immunosuppressive agents
  • ≥ CTCAE grade 3 immune-related AE (irAE) experienced with prior immunotherapy (except, non-clinically significant lab abnormalities (elevations in lipase, amylase not associated with clinically significant disease etc.) even if ≥ CTCAE grade 3 may enroll if resolved at this time, or, development of autoimmune disorders of Grade ≤ 3 may enroll if the disorder has resolved to Grade ≤ 1)
  • received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (except ≤ Grade 2 neuropathy)
  • autoimmune disorders of Grade 4 while on prior immunotherapy
  • active (i.e., symptomatic or growing) central nervous system (CNS) and/or leptomeningeal metastases (CNS lesions that are treated and deemed stable (repeat imaging study done at least 2 weeks prior to first dose of study treatment) are NOT permitted to enroll even if other inclusion criteria are met and patients are neurologically asymptomatic)
  • known additional malignancy that is progressing or requires active treatment (except, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy)
  • invasive cancer diagnosed and treated less than 2 years prior to current presentation (other indolent malignancies that are not progressing and/or deemed to require active therapy are not exclusionary)
  • evidence of interstitial lung disease or active, non-infectious pneumonitis
  • active infection requiring systemic therapy
  • history or current evidence of any condition, therapy, or laboratory abnormality determined to be significant, in the opinion of the treating investigator
  • known psychiatric or substance abuse disorders that would interfere with study compliance
  • is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial
  • had a live vaccine within 30 days of initiating protocol therapy
  • received prior therapy with an IDO inhibitor, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 and/or combination (including nivolumab, pembrolizumab or ipilimumab/nivolumab). Prior treatment with ipilimumab or interferon alfa is allowed.
  • history of allergic or hypersensitivity reaction to components or excipients of Dostarlimab (TSR-042) and TSR-022, interferon alfa or ipilimumab
  • known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
  • known history of or screening test that is positive for hepatitis B virus (HBV; eg, HBsAg reactive or HBV DNA detected) or hepatitis C virus (HCV; HCV antibody positive and/or HCV RNA quantitative is detected). Hepatitis C antibody - positive subjects who received and completed treatment for hepatitis C that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable. Hepatitis B positive subjects who received and completed treatment for hepatitis B that was intended to eradicate the virus may participate if hepatitis B DNA levels are undetectable.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04139902


Contacts
Layout table for location contacts
Contact: Diwakar Davar, MD 412-623-7368 davard@upmc.edu
Contact: Amy J Rose, BSN 412-647-8587 kennaj@upmc.edu

Locations
Layout table for location information
United States, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Contact: Amy J Rose, BSN    412-647-8587    kennaj@upmc.edu   
Principal Investigator: Diwakar Davar, MD         
Sponsors and Collaborators
Diwakar Davar
Tesaro, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Diwakar Davar, MD UPMC Hillman Cancer Center

Layout table for additonal information
Responsible Party: Diwakar Davar, Assistant Professor of Medicine, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT04139902    
Other Study ID Numbers: 19-047
First Posted: October 25, 2019    Key Record Dates
Last Update Posted: January 6, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas